Hydroxypropyl methylcellulose-based controlled release dosage by melt extrusion and 3D printing: Structure and drug release correlation

Zhang, Jiaxiang; Yang, Weiwei; Vo, Anh; Feng, Xinliang; Ye, Xingyou; Kim, Dong Wuk; Repka, Michael A.

doi:10.1016/j.carbpol.2017.08.058

Cited by 173 publications

(84 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is attributed to the closed, compact structure of the wall. This observation was consistent with the results of a previous study [34]. The tablets with 100% infill densities demonstrated pulse release at the end of 4.5 ± 0.26 h, followed by 75% infill (2 ± 0.22 h), and 50% infill (0.5 ± 0.19) ( Figure 7C).…”

Section: In Vitro Dissolution Studysupporting

confidence: 93%

Novel Gastroretentive Floating Pulsatile Drug Delivery System Produced via Hot-Melt Extrusion and Fused Deposition Modeling 3D Printing

2020

View full text Add to dashboard Cite

This study was performed to develop novel core-shell gastroretentive floating pulsatile drug delivery systems using a hot-melt extrusion-paired fused deposition modeling (FDM) 3D printing and direct compression method. Hydroxypropyl cellulose (HPC) and ethyl cellulose (EC)-based filaments were fabricated using hot-melt extrusion technology and were utilized as feedstock material for printing shells in FDM 3D printing. The directly compressed theophylline tablet was used as the core. The tablet shell to form pulsatile floating dosage forms with different geometries (shell thickness: 0.8, 1.2, 1.6, and 2.0 mm; wall thickness: 0, 0.8, and 1.6 mm; and % infill density: 50, 75, and 100) were designed, printed, and evaluated. All core-shell tablets floated without any lag time and exhibited good floating behavior throughout the dissolution study. The lag time for the pulsatile release of the drug was 30 min to 6 h. The proportion of ethyl cellulose in the filament composition had a significant (p < 0.05) effect on the lag time. The formulation (2 mm shell thickness, 1.6 mm wall thickness, 100% infill density, 0.5% EC) with the desired lag time of 6 h was selected as an optimized formulation. Thus, FDM 3D printing is a potential technique for the development of complex customized drug delivery systems for personalized pharmacotherapy.

show abstract

Section: In Vitro Dissolution Studysupporting

confidence: 93%

Novel Gastroretentive Floating Pulsatile Drug Delivery System Produced via Hot-Melt Extrusion and Fused Deposition Modeling 3D Printing

2020

View full text Add to dashboard Cite

show abstract

“…Overall, the weight uniformity of all the printed tablets, paracetamol and aspirin, ranges from a lower range of 1324 mg (paracetamol) to an upper range of 1918 mg (aspirin) with significant differences between some tablets being shown as previously outlined with the exception of significant differences between 2.50% Para and 5.00% Para. These findings reported here of dimensional accuracy and weight uniformity as well as the observations reported in the literature [22,45,54,[83][84][85][86] illustrate that AM and in particular the SLA process has the potential to be exploited in the fabrication of dosage forms for a variety of medical conditions. This is evident in the ability to print dosage forms comprised of various monomer(s)/photoinitiator(s)/drug concentrations and/or combinations of each which show excellent consistency in their dimensions with reference to the STL file that was imported into the software of the printer.…”

Section: Sla Formulationsupporting

confidence: 82%

Additive Manufacturing of Personalized Pharmaceutical Dosage Forms via Stereolithography

et al. 2019

View full text Add to dashboard Cite

The introduction of three-dimensional printing (3DP) has created exciting possibilities for the fabrication of dosage forms, paving the way for personalized medicine. In this study, oral dosage forms of two drug concentrations, namely 2.50% and 5.00%, were fabricated via stereolithography (SLA) using a novel photopolymerizable resin formulation based on a monomer mixture that, to date, has not been reported in the literature, with paracetamol and aspirin selected as model drugs. In order to produce the dosage forms, the ratio of poly(ethylene glycol) diacrylate (PEGDA) to poly(caprolactone) triol was varied with diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide (Irgacure TPO) utilized as the photoinitiator. The fabrication of 28 dosages in one print process was possible and the printed dosage forms were characterized for their drug release properties. It was established that both drugs displayed a sustained release over a 24-h period. The physical properties were also investigated, illustrating that SLA affords accurate printing of dosages with some statistically significant differences observed from the targeted dimensional range, indicating an area for future process improvement. The work presented in this paper demonstrates that SLA has the ability to produce small, individualized batches which may be tailored to meet patients’ specific needs or provide for the localized production of pharmaceutical dosage forms.

show abstract

“…Fused deposition modelling (FDM) 3D printing has therefore been proposed as an alternative method for 3D printing of tablets [16,17] and medical devices [18]. The method allows the fabrication of immediate [19][20][21], delayed [22,23], extended release tablets [24][25][26][27][28] as well as for dual drug delivery systems [29][30][31]. The technology offers several advantages such as the lower cost, absence of finishing step, small place requirement and obviation for material recycling [13,32].…”

Section: Introductionmentioning

confidence: 99%

‘Temporary Plasticiser’: A novel solution to fabricate 3D printed patient-centred cardiovascular ‘Polypill’ architectures

Pereira

Isreb

Forbes

et al. 2019

European Journal of Pharmaceutics and Biopharmaceutics

162

View full text Add to dashboard Cite

Hypertension and dyslipidaemia are modifiable risk factors associated with cardiovascular diseases (CVDs) and often require a complex therapeutic regimen. The administration of several medicines is commonly associated with poor levels of adherence among patients, to which World Health Organisation (WHO) proposed a fixed-dose combination unit (polypill) as a strategy to improve adherence. In this work, we demonstrate the fabrication of patient-specific polypills for the treatment of CVDs by fused deposition modelling (FDM) 3D printing and introduce a novel solution to meet critical quality attributes. The construction of poly(vinyl alcohol) (PVA)-based polypills containing four model drugs (lisinopril dihydrate, indapamide, rosuvastatin calcium and amlodipine besylate) was revealed for the first time. The impact of tablet architecture was explored using multi-layered and unimatrix structures. The novel approach of using distilled water as a 'temporary co-plasticiser' is reported and was found to significantly lower the extruding (90°C) and 3D printing (150°C) temperatures from 170°C and 210°C respectively, with consequent reduction in thermal stress to the chemicals. XRD indicated that lisinopril dihydrate and amlodipine besylate maintained their crystalline form while indapamide and rosuvastatin calcium were essentially amorphous in the PVA tablets. From the multilayer polypills, the release profile of each drug was dependent on its position in the multilayer.In addition to the multilayer architecture offering a higher flexibility in dose titration and a more adaptive solution to meet the expectations of patient-centred therapy, we identify that it also allows orchestrating the release of drugs of different physicochemical characteristics. Adopting such an approach opens up a pathway towards low-cost multidrug delivery systems such as tablets, stents or implants for wider range of globally approved actives.

show abstract

Hydroxypropyl methylcellulose-based controlled release dosage by melt extrusion and 3D printing: Structure and drug release correlation

Cited by 173 publications

References 46 publications

Novel Gastroretentive Floating Pulsatile Drug Delivery System Produced via Hot-Melt Extrusion and Fused Deposition Modeling 3D Printing

Novel Gastroretentive Floating Pulsatile Drug Delivery System Produced via Hot-Melt Extrusion and Fused Deposition Modeling 3D Printing

Additive Manufacturing of Personalized Pharmaceutical Dosage Forms via Stereolithography

‘Temporary Plasticiser’: A novel solution to fabricate 3D printed patient-centred cardiovascular ‘Polypill’ architectures

Contact Info

Product

Resources

About